The ROE as of November 2024 (TTM) for Enzon Pharmaceuticals, Inc. (ENZN) is 4.30%

According to Enzon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 4.30%. This represents a change of 43.98% compared to the average of 2.99% of the last 4 quarters.

Enzon Pharmaceuticals, Inc. (ENZN) Historical ROE (quarterly & annually)

How has ENZN ROE performed in the past?

The mean historical ROE of Enzon Pharmaceuticals, Inc. over the last ten years is 28.45%. The current 4.30% ROE has changed -84.89% with respect to the historical average. Over the past ten years (40 quarters), ENZN's ROE was at its highest in in the December 2015 quarter at 69.09%. The ROE was at its lowest in in the December 2016 quarter at -44.66%.

Enzon Pharmaceuticals, Inc. (ENZN) ROE by Quarter and Year

Discovering the peaks and valleys of Enzon Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Enzon Pharmaceuticals, Inc. (ENZN) Average ROE

How has ENZN ROE performed in the past?

The current ROE of Enzon Pharmaceuticals, Inc. (ENZN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Enzon Pharmaceuticals, Inc. (ENZN) ROE vs. Peers

How is ENZN’s ROE compared to its peers?

Enzon Pharmaceuticals, Inc.’s ROE is greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than Tempest Therapeutics, Inc. (-187.44%), greater than IO Biotech, Inc. (-86.56%), less than Molecular Pharmacology (USA), Ltd. (0%), less than Curative Biotechnology, Inc. (124.31%), less than Kineta, Inc. (0%), less than OncoVista Innovative Therapies, Inc. (934.78%), less than Neurobiological Technologies, Inc. (0%), less than Polydex Pharmaceuticals Limited (0%), less than Cyclacel Pharmaceuticals, Inc. (0%), greater than Living Cell Technologies Limited (-53.04%), less than MultiCell Technologies, Inc. (7.64%), greater than Institute of Biomedical Research Corp. (-85.05%), less than Health Sciences Group, Inc. (164.07%), less than Mymetics Corporation (131.12%), less than Eliem Therapeutics, Inc. (0%), less than Molecular Partners AG (11.39%), greater than Opthea Limited (-47.03%), greater than PureTech Health plc (-39.16%), less than Acrivon Therapeutics, Inc. Common Stock (360.15%), greater than null (-26.28%), greater than null (-47.95%),

Build a custom stock screener for Enzon Pharmaceuticals, Inc. (ENZN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enzon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Enzon Pharmaceuticals, Inc. (ENZN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Enzon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.